Monday, February 26, 2024
Immunis is a private biotechnology company researching and developing secretome products to address age-driven immune deficits. Immunis has developed a novel method to grow human cells for clinical use and direct them to become highly pure populations of defined cells that secrete factors which benefit immune system development, modulation, and health. With age, every person experiences a reduction of factors which benefit immune system development, modulation, and health; our technology allows replacement of those factors. Our investigational secretome product, IMMUNA, is all natural, all human, and represents a perfectly balanced set of immune modulators in naturally occurring relevant physiological concentrations.
CEO/Top Company Official
Hans Keirstead, PhD
Lead Product in Development
IMMUNA (formerly known as IMM01-STEM)
Development Phase of Primary Product
Number Of Unlicensed Products